ATE345781T1 - Drei verschiedene polymertypen enthaltende formulierung mit verzögerter freigabe - Google Patents

Drei verschiedene polymertypen enthaltende formulierung mit verzögerter freigabe

Info

Publication number
ATE345781T1
ATE345781T1 AT96904590T AT96904590T ATE345781T1 AT E345781 T1 ATE345781 T1 AT E345781T1 AT 96904590 T AT96904590 T AT 96904590T AT 96904590 T AT96904590 T AT 96904590T AT E345781 T1 ATE345781 T1 AT E345781T1
Authority
AT
Austria
Prior art keywords
polymers
different types
release formulation
delayed release
formulation containing
Prior art date
Application number
AT96904590T
Other languages
English (en)
Inventor
Prasad Pinnamaraju
Guohua Zhang
Original Assignee
Duramed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duramed Pharmaceuticals Inc filed Critical Duramed Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE345781T1 publication Critical patent/ATE345781T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT96904590T 1995-03-01 1996-02-08 Drei verschiedene polymertypen enthaltende formulierung mit verzögerter freigabe ATE345781T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/395,565 US5695781A (en) 1995-03-01 1995-03-01 Sustained release formulation containing three different types of polymers

Publications (1)

Publication Number Publication Date
ATE345781T1 true ATE345781T1 (de) 2006-12-15

Family

ID=23563579

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96904590T ATE345781T1 (de) 1995-03-01 1996-02-08 Drei verschiedene polymertypen enthaltende formulierung mit verzögerter freigabe

Country Status (9)

Country Link
US (1) US5695781A (de)
EP (1) EP0871435B1 (de)
JP (1) JPH11514332A (de)
AT (1) ATE345781T1 (de)
AU (1) AU706200B2 (de)
CA (1) CA2214100C (de)
DE (1) DE69636724T2 (de)
ES (1) ES2277340T3 (de)
WO (1) WO1996026717A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
US6074669A (en) * 1997-01-20 2000-06-13 Ranbaxy Laboratories Limited Controlled drug delivery system for diltiazem
IN186245B (de) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6251430B1 (en) * 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
DE19834172A1 (de) * 1998-07-29 2000-02-03 Benckiser Nv Zusammensetzung zur Verwendung in einem Wasserreservoir
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
FI121528B (fi) * 2000-10-30 2010-12-31 Biohit Oyj Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa
US20110171296A1 (en) * 2000-10-30 2011-07-14 Biohit Oyj Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US6465014B1 (en) * 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
WO2003037304A1 (en) * 2001-11-02 2003-05-08 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
DE10208344A1 (de) * 2002-02-27 2003-09-04 Roehm Gmbh Schmelzextrusion von Wirkstoffsalzen
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
EP1530458A1 (de) * 2002-08-14 2005-05-18 Ranbaxy Laboratories, Ltd. Matrixtabletten mit verlängerter wirkstoffabgabe
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
CA2569958C (en) 2004-06-12 2016-03-22 Jane C. Hirsh Abuse-deterrent drug formulations
ITMI20041255A1 (it) * 2004-06-22 2004-09-22 Univ Degli Studi Milano Sistemi microparticellari per somministrazione orale di sostanze biologicamente attive
PL1618873T3 (pl) * 2004-07-14 2008-01-31 Siegfried Generics Int Ag Granulat do kontrolowanego uwalniania tamsulozyny, zawierający alginian
JP2009500318A (ja) * 2005-06-29 2009-01-08 パナセア バイオテック リミテッド 新規な徐放性医薬組成物とその製法
US20070092573A1 (en) * 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP2090298A4 (de) * 2006-11-13 2014-02-26 Kyorin Seiyaku Kk Verfahren zur herstellung einer tablette mit verzögerter freisetzung
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
PL226261B1 (pl) * 2008-12-31 2017-07-31 Univ Jagielloński Kompozycja do przedłużonego uwalniania heparyny i zastosowanie żelu alginian-hydroksypropyloceluloza do przedłużonego uwalniania heparyny
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
SG10201510564PA (en) 2010-12-22 2016-01-28 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
ES2581323T3 (es) 2010-12-23 2016-09-05 Purdue Pharma Lp Formas de dosificación oral sólida resistentes a alteraciones
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP3878445A3 (de) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosat-formulierungen, verfahren zur verwendung davon und kombinationen damit
WO2017026950A1 (en) 2015-08-07 2017-02-16 Santa Farma Ilac San. A. S. Controlled release propiverine formulations
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
WO2020101586A1 (en) 2018-11-16 2020-05-22 Santa Farma İlaç Sanayi̇ A.Ş. Controlled release propiverine formulations
EP4251154A1 (de) 2020-11-27 2023-10-04 Santa Farma Ilac Sanayii A.S. Propiverin enthaltende formulierungszusammensetzungen mit verzögerter freisetzung
EP4262799A1 (de) * 2020-12-18 2023-10-25 Santa Farma Ilac Sanayii A.S. Homogene zusammensetzungen aus propiverin-hci-formulierungen

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1154810B (de) * 1961-04-01 1963-09-26 Knoll Ag Verfahren zur Herstellung basisch substituierter Phenylacetonitrile
DE2658500C2 (de) * 1976-12-23 1986-10-09 Knoll Ag, 6700 Ludwigshafen Pharmazeutische Präparate mit kardioprotektiver Wirkung
DE3113901A1 (de) * 1981-04-07 1982-10-28 Basf Ag, 6700 Ludwigshafen Wirkstoffzubereitung zur oralen applikation
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
US4800081A (en) * 1984-04-18 1989-01-24 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections
ATE32061T1 (de) * 1984-06-15 1988-02-15 Heumann Ludwig & Co Gmbh Verfahren zur herstellung basisch substituierter phenylacetonitrile.
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
DE3517820A1 (de) * 1985-05-17 1986-11-20 Röhm Pharma GmbH, 6108 Weiterstadt Pharmazeutische praeparate mit antihypertensiver und kardioprotektiver wirkung
LU86077A1 (fr) * 1985-09-18 1987-04-02 Pharlyse Sa Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques
LU86099A1 (fr) * 1985-09-30 1987-04-02 Pharlyse Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
DE3535950A1 (de) * 1985-10-09 1987-04-09 Basf Ag Kombinationspraeparat
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
US4654372A (en) * 1986-01-10 1987-03-31 Warner-Lambert Company Method for using verapamil for treating stroke
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
NZ223619A (en) * 1987-02-27 1990-10-26 Lilly Co Eli Sustained release tablet containing cefaclor, a hydrophilic polymer and an acrylic polymer
US4981871A (en) * 1987-05-15 1991-01-01 Abelson Mark B Treatment of ocular hypertension with class I calcium channel blocking agents
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
IE64726B1 (en) * 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
US5230901A (en) * 1988-03-23 1993-07-27 Knoll Ag Sustained release tablet of a mixture of alginates and polyacrylates
ES2045281T3 (es) * 1988-07-13 1994-01-16 Knoll Ag Forma de medicamento de accion retardada sobre la base de alginatos.
US4952672A (en) * 1988-08-11 1990-08-28 The Dow Chemical Company Method for the devolatilization of thermoplastic materials
US5169639A (en) * 1988-09-19 1992-12-08 Edward Mendell Co., Inc. Controlled release verapamil tablets
US5350771A (en) * 1989-03-22 1994-09-27 Peter K. T. Pang Method and treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers
US5089502A (en) * 1989-06-02 1992-02-18 E. R. Squibb & Sons, Inc. Method for preventing or treating anxiety employing a calcium channel blocker
US5132119A (en) * 1989-07-31 1992-07-21 Massachusetts Institute Of Technology Treatment of hypertrophic wound healing disorders with calcium channel blockers
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen

Also Published As

Publication number Publication date
AU4865596A (en) 1996-09-18
US5695781A (en) 1997-12-09
EP0871435A1 (de) 1998-10-21
CA2214100C (en) 2008-06-10
JPH11514332A (ja) 1999-12-07
EP0871435B1 (de) 2006-11-22
EP0871435A4 (de) 1999-07-07
DE69636724T2 (de) 2007-09-20
DE69636724D1 (de) 2007-01-04
WO1996026717A1 (en) 1996-09-06
ES2277340T3 (es) 2007-07-01
CA2214100A1 (en) 1996-09-06
AU706200B2 (en) 1999-06-10

Similar Documents

Publication Publication Date Title
ATE345781T1 (de) Drei verschiedene polymertypen enthaltende formulierung mit verzögerter freigabe
CA2312710A1 (en) Sustained release formulation containing three different types of polymers and tablet formed therefrom
ATE222753T1 (de) Oxybutyninformulierungen mit gesteuerter freisetzung
DE69432025D1 (de) Formulierungen mit verzögerter freisetzung zur abgabe von metoprolol über 24 stunden
DK1107791T3 (da) Hydrogelpræparater til controlled release-administration af vækstfaktorer
DE59202537D1 (de) Feste pharmazeutische Retardform.
PT93384A (pt) Processo para a preparacao de um material de revestimento de controlo da libertacao de droga para formulacoes de accao prolongada contendo copolimeros de (met)acrilato
BR9000418A (pt) Composicao de spray para cabelos e processo para a producao da mesma
DE69622510D1 (de) Nifedipinzubereitung mit langanhaltender Freisetzung
NO20001042D0 (no) Oftalmiske preparater med forsinket frigivelse inneholdende vannoppløselige medikamenter
HRP20010463B1 (en) Controlled release galantamine composition
NO175240C (no) Fremgangsmåte for fremstilling av et langsomt frigivende farmasöytisk preparat som omfatter sekundære granuler
DK0744940T3 (da) Medikamenter, vacciner og hormoner i polylactidovertrukne mikrokugler
DE69934582D1 (de) Delavirdin tablettenformulierung
ATE260648T1 (de) Überzugs- und bindemittel für arzneiformen sowie damit hergestellte arzneiform
DK0923934T3 (da) Modified release-matrixformulering af cefaclor og cephalexin
ATE69725T1 (de) Pharmazeutische zubereitungen von acrivastine.
PT954290E (pt) Comprimido farmaceutico de libertacao controlada contendo um suporte a base de amilose reticulada e de hidroxipropilmetilcelulose.
WO1998022097A3 (en) Controlled release matrix composition using polar polymer or monomer and poly(acrylic acid) blend
IS1620B (is) Aðferð til framleiðslu á lyfjablöndum sem innihalda nifedipine
PT885014E (pt) Composicoes farmaceuticas contendo polimeros orto ester tamponados
DK1169032T3 (da) Ketoprofen-mikrogranuler, fremgangsmåde til fremstilling deraf og farmaceutiske præparater
CA2085871A1 (en) A controlled release drug dispersion delivery device
TW327602B (en) A pharmaceutical composition of an ophthalmic suspension containing difluprednate
IT1256743B (it) Composizioni farmaceutiche a rilascio controllato contenenti nicergolina

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties